abrdn plc Has $17.63 Million Stock Position in DaVita Inc. (NYSE:DVA)

abrdn plc raised its holdings in DaVita Inc. (NYSE:DVA) by 17.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 168,316 shares of the company’s stock after buying an additional 24,966 shares during the quarter. abrdn plc’s holdings in DaVita were worth $17,633,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Deutsche Bank AG boosted its stake in DaVita by 421.8% during the third quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after acquiring an additional 885,195 shares in the last quarter. Invesco Ltd. boosted its position in shares of DaVita by 21.3% during the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock worth $157,606,000 after purchasing an additional 292,767 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of DaVita by 148.8% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 365,701 shares of the company’s stock valued at $34,570,000 after buying an additional 218,693 shares during the period. Northern Trust Corp increased its position in DaVita by 15.7% in the 3rd quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after buying an additional 113,508 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in DaVita by 2,178.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock worth $11,379,000 after buying an additional 103,856 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on DVA shares. UBS Group lifted their price target on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Truist Financial increased their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. Barclays started coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price for the company. Finally, TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Trading Down 0.9 %

Shares of DaVita stock opened at $132.75 on Thursday. The firm has a market cap of $11.64 billion, a PE ratio of 17.94, a P/E/G ratio of 1.19 and a beta of 1.04. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The stock has a fifty day moving average price of $131.63 and a 200-day moving average price of $110.00.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.11 earnings per share. Equities research analysts anticipate that DaVita Inc. will post 9.23 EPS for the current year.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares in the company, valued at $2,424,384.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock worth $16,551,071 in the last quarter. Insiders own 1.40% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.